Last updated on January 2019

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes With a FRC Extension Period


Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 8400063
Houston, TX United States
1.6miles

Trial Transparency email recommended (Toll ...

Investigational Site Number 8400106
Houston, TX United States
1.6miles

Trial Transparency email recommended (Toll ...

Investigational Site Number 8400008
Houston, TX United States
5.93miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.